Longeveron Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Longeveron's Phase 2b ELPIS II trial of laromestrocel for hypoplastic left heart syndrome (HLHS) in 40 infants failed its primary endpoint (right ventricular ejection fraction at 12 months, p=0.68). However, the pre-specified secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance: 8 events in standard-of-care arm vs. 1 in laromestrocel arm (p=0.043), with no treatment-related serious adverse events. Data selected for AHA 2026 podium presentation (November 8, 2026). Company plans FDA meeting to discuss next steps.
Why this rating
Primary endpoint failure is material negative; secondary MACE significance is modest positive. At $16.5M market cap, clinical trial outcome for lead program directly affects company viability and funding prospects. FDA path unclear but MACE result provides partial support for continued development.
Price action (we called it positive)
before filing · preread $1.60 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.